Semaglutide dose-dependently reduces fentanyl self-administration and motivation in female rats
Background
The global opioid use disorder (OUD) crisis, driven significantly by fentanyl, continues to cause substantial morbidity and mortality. Despite the availability of three FDA-approved medications, major barriers to access and efficacy gaps persist, highlighting an urgent need for novel therapeutic strategies. Previous research has indicated that glucagon-like peptide-1 (GLP-1) receptor agonists may modulate addictive behaviors, making them a promising area for investigation into OUD treatment.
Study Design
Female Wistar rats (N=32) were surgically implanted with jugular catheters and trained to self-administer fentanyl on a fixed-ratio 1 (FR1) schedule for 21 sessions, under either short-access (ShA; 1 hour) or long-access (LgA; 8 hours) conditions. Animals then received semaglutide (0.1 mg/kg, s.c.) or saline (0.9% NaCl, s.c.) before another FR1 session. A progressive ratio (PR) schedule followed, with semaglutide (0.1 mg/kg, s.c.) or saline, alongside fentanyl (0.625-10 µg/kg/inf, i.v.) or saline (i.v.). A semaglutide (0-0.1 mg/kg, s.c.) dose-response was assessed at FR1 with fentanyl (2.5 µg/kg/inf, i.v.). Post-discontinuation, spontaneous locomotor activity and withdrawal-like symptoms were measured.
Results
Semaglutide dose-dependently decreased fentanyl rewards under both ShA and LgA conditions (p<0.05). This reduction in self-administration suggests a direct impact on drug intake. Under a progressive ratio (PR) schedule, semaglutide significantly decreased the breakpoint (p<0.05), indicating a reduced motivation to seek fentanyl. This finding is crucial as it points to a potential modulation of the underlying drive for drug reward. Furthermore, semaglutide-treated ShA animals displayed significantly less withdrawal-like behavior (p<0.05) compared to controls, suggesting a protective effect against acute withdrawal symptoms. However, this effect was not observed in LgA animals, implying potential differences in how semaglutide impacts withdrawal based on the duration of drug access. The dose-response procedure confirmed the efficacy of semaglutide across a range of doses. Overall, these findings strongly suggest that semaglutide can modulate the motivation to seek opioid reward.
Semaglutide significantly decreased breakpoint in progressive ratio testing (p<0.05), demonstrating reduced motivation to self-administer fentanyl.
Key Findings
- Semaglutide dose-dependently reduced fentanyl self-administration in female rats (p<0.05).
- Motivation to seek fentanyl, measured by breakpoint, significantly decreased with semaglutide (p<0.05).
- Short-access (ShA) semaglutide-treated rats showed significantly less withdrawal-like behavior (p<0.05).
- The protective effect against withdrawal was not observed in long-access (LgA) animals.
Why It Matters
This preclinical study suggests semaglutide could emerge as a novel pharmacotherapy for Opioid Use Disorder (OUD), offering a new avenue for treatment beyond current options. The ability of semaglutide to reduce both fentanyl self-administration and the motivation to seek the drug is a significant finding, potentially addressing core aspects of addiction. Given semaglutide's established safety profile and once-weekly dosing in humans for other indications, its repurposing for OUD could streamline clinical translation. While these findings are from female rats, they provide a strong rationale for further investigation, including studies in male animals and, eventually, human clinical trials. This research could lead to new protocols that incorporate GLP-1 agonists to reduce opioid cravings and withdrawal severity.
semaglutide
fentanyl
opioid-use-disorder
addiction
glp-1-agonist
preclinical-animal